Volume 3.27 | Jul 14

Cord Blood News 3.27, July 14, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Cord Blood News on Twitter

HLA Mismatch Direction in Cord Blood Transplantation: Impact on Outcome and Implications for Cord Blood Unit Selection
To identify possible “permissive” mismatches, researchers examined the relationship between direction of HLA mismatch and transplant outcomes in 1,202 recipients of single cord blood units from the New York Blood Center National Cord Blood Program treated in US Centers from 1993 to 2006. [Blood]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

The Role of Fibrin E on the Modulation of Endothelial Progenitors Adhesion, Differentiation and Angiogenic Growth Factor Production and the Promotion of Wound Healing
Here researchers tested the importance of different extracellular matrices in regulating the angiogenic and wound healing potential of cord blood-derived endothelial progenitor cells. [Biomaterials]

Family-Directed Umbilical Cord Blood Banking
In order to provide a better service for families in need, directed-family cord blood banking activities should be encouraged and closely monitored with common standards and better information on current and future indications. [Haematologica]

Neurogenic Properties and a Clinical Relevance of Multipotent Stem Cells Derived from Cord Blood Samples Stored in the Biobanks
Here researchers have compared 5 major methods of blood processing: Sepax, Hetastarch, Plasma depletion, Prepacyte-SC and Density gradient. [Stem Cells Dev]

MicroRNA and Messenger RNA Analyses of Mesenchymal Stem Cells Derived from Teeth and the Wharton Jelly of Umbilical Cord
In this study, researchers integrated the use of microRNA and mRNA expression profiles to analyze human mesenchymal stem cells derived from Wharton’s jelly of the umbilical cord, milk teeth, and adult wisdom teeth. [Stem Cells Dev]

Ultra High Yield Manufacture of Red Blood Cells from Hematopoietic Stem Cells
Researchers successfully developed a robust ultra-high yield red blood cell (RBC) expansion process capable of producing over 500 units of RBC per umbilical cord blood donation using fully defined culture medium. [Tissue Eng Part C Methods]

Reduced-Intensity Conditioning Hematopoietic SCT for Pediatric Patients with LAD-I: Clinical Efficacy and Importance of Chimerism
This study attempts to show that reduced-intensity regimen leads to a favorable result in leukocyte adhesion deficiency type-I (LAD-I) patients even in those who have experienced comorbid complications. [Bone Marrow Transplant]

Activated T Cells from Umbilical Cord Blood Armed with Anti-CD3 × Anti-CD20 Bispecific Antibody Mediate Specific Cytotoxicity Against CD20+ Targets with Minimal Allogeneic Reactivity: A Strategy for Providing Antitumor Effects After Cord Blood Transplants
In this study, researchers asked whether anti-CD3–activated T cells (ATCs) from cord blood (CB) could be expanded and targeted to solid tumors or hematologic malignancies for infusions after unrelated CB stem cell transplant and whether cord blood ATCs could reduce alloresponsiveness. [Transfusion]

Pharmacokinetics-Based Optimal Dose Prediction of Donor Source-Dependent Response to Mycophenolate Mofetil in Unrelated Hematopoietic Cell Transplantation
Data from 36 unrelated allogeneic bone marrow and cord blood transplantations were analyzed retrospectively based on mycophenolic acid area under the curve (AUC0–24h). [Int J Hematol]



The Gamida Cell-Teva Joint Venture Receives Green Light from the Data Monitoring Committee to Continue the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
The Gamida Cell-Teva Joint Venture (JV) announced that the Data Monitoring Committee has independently reviewed data collected from the first 70 patients enrolled in the pivotal registration, Phase III clinical trial of StemEx and has recommended that the JV continue to enroll patients in the StemEx study. [Gamida Cell Ltd. Press Release]

Cryo-Cell International, Inc. Reports Second Quarter 2011 Results
Cryo-Cell International, Inc. announced results for the second quarter ended May 31, 2011. [Cryo-Cell International, Inc. Press Release]

China Cord Blood Corporation Continues Share Repurchase Program
China Cord Blood Corporation announced that the Company repurchased an aggregate of 2,052,607 ordinary shares. [China Cord Blood Corporation Press Release]

£4 Million Investment in NHS Stem Cell Services
The Government announced a £4 million investment in National Health Service (NHS) stem cell services. [National Health Service, United Kingdom Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Conference on Regenerative Medicine
November 2-4, 2011
Leipzig, Germany

Visit our events page to see a complete list of events in the cord blood community.
Scientist (iPSC) (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Industrial Postdoctoral Research Fellow (Regenerative Medicine Cell Therapy) (Tissue Regeneration Therapeutics Inc.) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us